Zymergen was a synthetic biology and biofacturing company that used machine learning and artificial intelligence to engineer microbes to produce novel biomolecules for manufacturing. The company developed proprietary automation, software, and data science tools to manufacture products sustainably.
Zymergen is publicly traded
IPO'd on April 22, 2021
This company is no longer available on our private secondary market. Shares can be traded publicly under ZY.
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2013
Total Funding
$874M
5 rounds
Last Private Valuation
$1.75B
September 2020
Total raised $874M across 5 rounds
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Last updated 06-25-2026
Latest Round
Type
Series D
Date
September 2020
Amount
$300M
Valuation
$1.75B
Lead Investors
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| September 2020 | Series D | $300M | $1.75B | Baillie Gifford |
| December 2018 | Series C | $400M | — | SoftBank Vision Fund |
| October 2016 | Series B | $130M | — | SoftBank Capital |
Joshua Hoffman
Founder, Former CEO
Zach Serber
Co-Founder
Jed Dean
Co-Founder
Jay Flatley
CEO, Chairman
Competitor list is illustrative and may be incomplete, stale, or erroneous.
Ginkgo Bioworks
Synthetic biology platform company that engineers microorganisms for industrial applications; acquired Zymergen in October 2022
Intrexon Corporation
Genetic engineering and synthetic biology company focused on bioindustrial applications
Synthego Corporation
Synthetic biology company providing gene editing tools and services
Zymergen Competitors
Competitors in engineered biology and biofacturing space
Yes, Zymergen is publicly traded under the ticker symbol ZY on the NASDAQ. The company went public in April 22, 2021.
Zymergen trades under the ticker symbol ZY on the NASDAQ. It began trading in April 22, 2021.
Zymergen (ZY on the NASDAQ) shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker ZY to place an order.
Zymergen went public in April 22, 2021 via ipo, with an offering valuation of approximately $1.75B. Zymergen went public via IPO on April 22, 2021, priced at $31/share for 16.13M shares, raising $500M and valuing the company at $3B. The stock opened 30% higher on its first day. However, the company faced significant challenges post-IPO. In July 2021, SEC filings revealed only $13M in 2020 revenue and $262M in losses. In August 2021, the company disclosed that its primary product Hyaline was unsuccessful with customers and announced CEO Joshua Hoffman's resignation. The stock subsequently collapsed. In July 2022, Ginkgo Bioworks agreed to acquire Zymergen for $300M in an all-stock transaction (0.9179 Ginkgo shares per Zymergen share). The acquisition was completed on October 19, 2022, with the stock delisted from NASDAQ. Zymergen later filed for Chapter 11 bankruptcy on October 3, 2023, with Ginkgo's Plan of Liquidation confirmed in February 2024.
Zymergen raised $874M across 5 disclosed funding rounds prior to its public listing.
Zymergen was co-founded by Joshua Hoffman, Zach Serber, and Jed Dean in 2013.
Zymergen is headquartered in Emeryville, CA.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.